Desh Rakshak (531521)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at a steep discount to book value: P/B of 0.57 against a book value of ₹17.92 and price of ₹10.20.
• Positive ROE and ROCE of 6.49% and 6.89%, suggesting the existing asset base is not entirely idle.
• Ongoing revenue generation, albeit tiny at ₹1 crore in the latest quarter.
• Microcap size of ₹5 crore market cap could offer outsized returns if the business stabilizes and re-rates.

Concerns

• Sales growth of -25.53% and profit growth of -25.00%; latest quarter net profit is ₹0.
• Piotroski F-Score of 3/9 signals weak financial health and deteriorating fundamentals.
• No dividend yield; shareholders receive no income while waiting for recovery.
• Critical data missing: debt/equity, promoter holding, and FairStock Score are N/A, making thorough due diligence impossible.

AI Analysis

At first glance, Desh Rakshak appears to be a classic Graham bargain: the market prices it at ₹10.20 while the book value stands at ₹17.92, a P/B of only 0.57. But the price of a stock is not the value of the business. This is a ₹5 crore market cap pharmaceutical company with no meaningful earnings power. Sales have contracted 25.53%, profits have fallen by 25.00%, and the latest quarter shows sales of ₹1 crore and net profit of ₹0. The trailing P/E of 22.05 looks absurd when current earnings are near zero. ROE of 6.49% and ROCE of 6.89% are mediocre; they tell me the assets are not being deployed productively. The Piotroski F-Score of 3/9 reinforces my caution: this is not a healthy financial picture. No dividend is paid, promoter holding is not disclosed, and even the FairStock score says insufficient data. A low price-to-book value can be a trap if the book value is impaired, if there are hidden liabilities, or if the business cannot generate returns above the cost of capital. In this case, I have no evidence of a moat, a pricing advantage, or a durable product franchise. The collapse from a 52-week high of ₹84.30 to ₹10.20 tells me the market has already repriced expectations, and falling sales suggest the bad news may not be over. Ben Graham would want a margin of safety in tangible assets and a clear path to earnings recovery; I don't see that path from these numbers. With inadequate data and deteriorating operations, this feels more like a balance sheet speculation than a quality investment. I would need to access audited financials, cash flow, debt details, and management's capital allocation history before risking my money. As Buffett says, it is far better to buy a wonderful company at a fair price than a fair company at a wonderful price. On the evidence available, Desh Rakshak is not wonderful.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer